The past decade has witnessed the emergence of the next wave of biomarkers for PCa that introduced novel assays in serum or urine, supplementing or, in time, replacing PSA due to their higher specificity, such as PHI, 4Kscore, PCA3, and ExoDx. Here, KLK3 is linked to posterior cortical atrophy.